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The impact of metabolic syndrome on 
the antiplatelet effect of clopidogrel and 
aspirin in patients with acute coronary 
syndrome
ABSTRACT
Aim. The aim of this study was to evaluate the impact of metabolic syndrome and features clustering in 
this syndrome on the antiplatelet effect of clopidogrel and aspirin in patients with myocardial infarction.
Material and methods. The study population comprised 186 consecutive patients treated with primary 
percutaneous coronary intervention for acute myocardial infarction. Measurements of ADP induced platelet 
aggregation (ADP-PA) and arachidonic acid induced platelet aggregation (AA-PA) were performed using 
impedance aggregometry with a Multiplate Analyser. The following factors were analysed as potential 
determinants of responsiveness to clopidogrel and to aspirin: diagnosed metabolic syndrome, diabetes, 
hypertension, abdominal obesity, body mass index (BMI), and serum concentrations of triglycerides, 
HDL-cholesterol and high sensitivity C-reactive protein (hsCRP).
Results. The ADP-PA was significantly higher in patients with metabolic syndrome and with diabe-
tes. The AA-PA was significantly higher in subjects with increased levels of hsCRP and in subjects with 
BMI > 25 kg/m2. The hsCRP was found to be the only independent factor influencing APD-PA (p=0.034). 
Serum concentrations of hsCRP, HDL-cholesterol and abdominal obesity were independent factors influ-
encing AA-PA (p=0.000004). 
Conclusion. Metabolic syndrome, diabetes mellitus, obesity and increased hsCRP are determinants of 
low responsiveness to aspirin and clopidogrel in patients with ACS treated with PCI.
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Introduction
A dual antiplatelet therapy with clopidogrel and aspirin 
has been shown to reduce the risk of major adverse car-
diovascular events after percutaneous coronary interven-
tion. However, a substantial proportion of patients do not 
respond to such therapy sufficiently [1–4]. Several factors 
behind this poor response to treatment in patients with 
acute coronary syndromes (ACS), including drug-drug 
interactions, diabetes, genetic factors and other biological 
factors, such as inflammation and platelet activation due 
to plaque rupture, should be taken into account [3, 5–9]. 
Patients with diabetes as well as those with metabolic 
syndrome are characterised by a prothrombotic state that 
includes increased platelet reactivity [10–12]. Antiplatelet 
therapy in these pathological conditions is still a matter of 
intense debate, especially because of the high prevalence 
of resistance to these drugs. 
The aim of this study was to evaluate the impact 
of metabolic syndrome and features clustering in this 
syndrome on the antiplatelet effect of clopidogrel and 
aspirin in patients with myocardial infarction.
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Methods
Study design and patients characteristics
This was a prospective, observational, single-centre 
study. The study population comprised 186 consecutive 
patients treated with primary percutaneous coronary in-
tervention (pPCI) for acute ACS. Exclusion criteria were 
defined as follows: the need for prolonged use of hepa-
rin or fondaparinux, oral anticoagulant therapy, bleeding 
disorders (including thrombocytopenia <100 × 103/μl), 
anaemia with haemoglobin (HGB) < 10.0 g/dL, active 
inflammation, congestive heart failure (CHF) in NYHA 
classes III and IV, and life expectancy < 1 year. In-hos-
pital management and discharge treatment recom-
mendations strictly adhered to the European Society 
of Cardiology guidelines. Patients received a 600 mg 
loading dose and 75 mg maintenance dose of clopido-
grel in combination with aspirin doses of 300 mg and 
75 mg, respectively. To avoid additional confounding 
factors, concomitant therapy was standardised and 
included bisoprolol, perindopril and simvastatin if no 
contraindications were present. When therapy with 
proton pump inhibitor was indicated, only pantoprazole 
was allowed. In case of a necessity to use additional 
medication, drugs with known or potential drug–drug 
interaction with clopidogrel were avoided. Study pop-
ulation characteristics are set out in Table 1.
The following factors were analysed as potential 
determinants of responsiveness to clopidogrel and 
to aspirin: diagnosed metabolic syndrome, diabetes, 
hypertension, abdominal obesity, body mass index 
(BMI kg/m2), serum concentrations of triglycerides, 
high-density lipoprotein cholesterol (HDL-C), and high 
sensitivity C-reactive protein (hsCRP). The International 
Diabetes Federation definition of metabolic syndrome 
was applied: central obesity (waist size more than 94 cm 
in males or more than 80 cm in females) and any two 
of the following: raised triglycerides: > 150 mg/dL or 
specific treatment for this lipid abnormality; reduced 
HDL cholesterol: < 40 mg/dL in males, < 50 mg/dL in 
females or specific treatment for this lipid abnormality; 
raised blood pressure (BP): systolic BP > 130 or 
diastolic BP > 85 mm Hg or treatment of previously 
diagnosed hypertension; raised fasting plasma glucose 
(FPG): > 100 mg/dL or previously diagnosed type 2 di-
abetes. Measurements of biochemical parameters were 
performed in the Department of Laboratory Medicine, 
University Hospital, CM, NCU. 
The study protocol has been approved by The 
Ethical Committee of Nicolaus Copernicus University. 
Platelet function assessment
Blood samples were collected into hirudin-con-
taining tubes (Dynabyte Medical, Munich, Germa-
Table 1. Characteristics of study population according  
to median (upper quartile–lower quartile) or number 
(percent)
Feature
Whole population 
(n = 186)
Age (years) 60.0 (53.0–67.0)
Gender (male) 138 (74.2%)
STEMI 158 (84.9%)
NSTEMI 28 (15.1%)
Metabolic syndrome 76 (40.9%)
Abdominal obesity 121 (65.1%)
BMI [kg/m2] 27.7 (24.9–30.8)
Arterial hypertension 104 (55.9%)
Diabetes 64 (34.4%) 
Total cholesterol [mg/dL] 213.0 (177.0–240.0)
LDL-C [mg/dL] 139.0 (115.0–170.0)
HDL-C [mg/dL] 40.0 (34.5–47.5)
TG [mg/dL] 100.5 (70.5–152.5)
hsCRP [mg/l] 10.8 (4.9–31.5)
ADP-PA [U] 25.0 (17.0–37.0)
AA-PA [U] 12.5 (7.0–20.0)
BT [min] 5.0 (4.0–6.5)
STEMI — ST elevation myocardial infarction; NSTEMI — non-
-ST elevation myocardial infarction; BMI — body mass index; 
LDL-C — low-density lipoprotein-cholesterol; HDL-C — high-density 
lipoprotein-cholesterol; TG — triglycerides; hsCRP — high-sensitivity 
C-reactive protein; ADP-PA — ADP induced platelet aggregation; 
AA-PA — arachidonic acid induced platelet aggregation; BT — bleed-
ing time
ny) at 10.00 a.m. on the 4th day of hospitalisation. 
Measurements of ADP induced platelet aggregation 
(ADP-PA) and arachidonic acid induced platelet ag-
gregation (AA-PA) were performed using impedance 
aggregometry. Whole blood was tested with a Multi-
plate Analyser (Medical Cyclotron, Munich, Germany). 
One Multiplate test cell incorporates two independent 
sensor units, each consisting of two silver-coated 
highly conductive wires. When activated platelets 
adhere onto the sensor wires, the electrical resis-
tance between the wires rises, which is continuously 
registered. The instrument detects the impedance 
change of each sensor separately and transforms it 
into arbitrary aggregation units (AU) that are plotted 
against time. The area under the aggregation curve 
(AUC) is an estimator of platelet aggregation, and 
as such was evaluated in our study. It is affected by 
the total height of the AUC as well as by its slope, 
and is best suited to express overall platelet activity. 
Aggregation, quantified as the area under the curve, 
is displayed in arbitrary units [U]. 
68
folia Medica copernicana 2014, vol. 2, no 2
www.fmc.viamedica.pl
Table 2. ADP–PA, AA–PA and BT values with regard to analysed factors
Factor ADP-PA AA-PA BT
Metabolic syndrome (+) n = 76
Metabolic syndrome (–) n = 110
28.5 (19.5–40.0)
23.0 (15.0–36.0)
13.5 (9.0–22.0)
12.0 (6.0–20.0)
5.0 (3.75–6.5)
5.0 (4.0–7.0)
Abdominal obesity (+) n = 121
Abdominal obesity (–) n = 65
27.0 (18.0–38.0)
22.0 (16.0–35.0)
13.0 (7.0–21.0)
12.0 (7.0–20.0)
5.0 (4.0–6.5)
5.0 (3.5–7.0)
BMI > 25 kg/m2 n = 136
BMI ≤ 25 kg/m2 n = 50
27.0 (18.0–37.0)
21.0 (14.0–41.0)
14.0 (8.0–21.0)
10.0 (5.0–17.0)
5.0 (3.75–6.0)
5.5 (4.5–7.0)
Arterial hypertension (+) n = 104
Arterial hypertension (–) n = 82
27.0 (18.5–37.5)
23.0 (14.0–37.0)
12.5 (8.0–19.0)
12.5 (6.0–21.0)
5.0 (4.0–6.0)
5.0 (3.5–7.0)
Diabetes (+) n = 64
Diabetes (–) n = 122
30.0 (19.0–41.0)
24.0 (16.0–34.0)
14.5 (9.0–22,0)
12.0 (7.0–19.0)
5.0 (3.5–6.5)
5.0 (4.0–6.5)
HDL-C<50mg/dl (F);<40mg/dL (M) n = 107
HDL-C≥50mg/dl (F);≥40mg/dL (M) n = 78
25.0 (17.0–37.0)
24.5 (17.0–37.0)
13.0 (6.0–20.0)
12.0 (8.0–20.0)
5.0 (4.0–6.5)
4.5 (3.5–6.5)
TG ≥ 150 mg/dL n = 53
TG < 150 mg/dL n = 133
30.0 (18.0–41.0)
24.0 (16.0–35.0)
13.0 (8.0–22.0)
12.0 (7.0–20.0)
4.5 (3.5–6.0)
5.5 (4.0–7.0)
hsCRP > 3.0 mg/L n = 157
hsCRP ≤ 3.0 mg/L n = 25
26.0 (17.0–40.0)
23.0 (16.0–31.0)
13.0 (8.0–21.0)
8.0 (3.0–16.0)
8.0 (3.0–16.0)
4.5 (4.0–6.5)
p < 0.05; p ≥ 0.05
ADP-PA — ADP induced platelet aggregation; AA-PA — arachidonic acid induced platelet aggregation; BT — bleeding time; BMI — body mass 
index; HDL-C — high-density lipoprotein-cholesterol; TG — triglycerides; hsCRP — high-sensitivity C-reactive protein
Bleeding time (BT) measurements
For the measurements of bleeding time, the patients 
were seated with arm supine on a steady support with 
the volar surface exposed. Incision site was located on 
the muscular area of the forearm distal to the antecubital 
fossa. The skin was cleansed with alcohol and allowed 
to dry for at least 30 seconds. The sphygmomanometer 
cuff was placed on the arm and inflated to 40 mm Hg 
to cause a venous stasis. The puncture was performed 
using a Medlance® incision device with 21G needle 
and 2.4 mm penetration depth. After the incision was 
made, the timer was started. The flow was gently blotted 
with filter paper every 30 seconds until blood no longer 
stained the paper. The time from when the incision was 
made until the bleeding stopped was recorded. If the 
incision continued to bleed for more than ten minutes, 
the measurement was stopped and the result was re-
corded as > 10 minutes.
Statistical analysis
According to the Shapiro-Wilk test, the investigated 
continuous variables were non-normally distributed, 
therefore they were reported as medians and inter-
quartile ranges (IR). For comparisons between two and 
three groups, the Mann-Whitney unpaired rank sum test 
and the Kruskal–Wallis one-way analysis of variance 
were used, respectively. Categorical variables were 
expressed as a number of patients presenting the given 
feature and a percentage of patients in the analysed 
group. Categorical variables were compared using the 
c2 test with the Yates’ correction if required. The Co-
chran–Armitage test was used to assess the presence of 
a linear trend among categorical variables. Differences 
were considered significant at p < 0.05. The statistical 
analysis was carried out using the Statistica 10.0 pack-
age (StatSoft, Tulsa, OK, USA). Univariate and multivar-
iate logistic regression models were used. Variables 
with a p-value of ≤ 0.1 in the univariate analysis were 
introduced into the multivariate logistic regression mod-
el. Subsequently, variables with no significant impact 
on the prevalence of the efficacy end-points (p ≥ 0.05) 
were one by one removed from the multivariate model 
according to their decreasing p-values. 
Results
Comparative analysis of ADP-PA, AA-PA and BT 
values with regard to metabolic syndrome, abdominal 
obesity, BMI, arterial hypertension, diabetes, serum con-
centration of HDL-cholesterol, triglycerides and hsCRP 
was performed (Tab. 2). The ADP-PA was significantly 
higher in patients with metabolic syndrome (Fig. 1), as 
well as in individuals with diabetes (Fig. 2), while AA-PA 
was significantly higher with increased levels of hsCRP 
(Fig. 3) and in subjects with BMI > 25 kg/m2 (Fig. 4). 
The ADP-PA weakly correlated with hsCRP and with 
BMI (Tab. 3). Average correlation between AA-PA and 
hsCRP was found. Moreover, AA-PA weakly correlat-
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Figure 1. Comparison of ADP-PA, AA-PA and BT values 
in patients with and without metabolic syndrome. 
ADP-PA — ADP induced platelet aggregation; AA-PA 
— arachidonic acid induced platelet aggregation; BT 
— bleeding time
Figure 2. Comparison of ADP-PA, AA-PA and BT 
values in patients with and without diabetes. ADP-PA 
— ADP induced platelet aggregation; AA-PA — ara chi - 
donic acid induced platelet aggregation;BT — bleed-
ing time
Figure 3. Comparison of ADP-PA, AA-PA and BT values in 
patients with hsCRP > 3.0 mg/L versus hsCRP ≤ 3.0 mg/L. 
ADP-PA — ADP induced platelet aggregation; AA-PA 
— arachidonic acid induced platelet aggregation; BT 
— bleeding time; hsCRP — high-sensitivity C-reactive protein
Figure 4. Comparison of ADP-PA, AA-PA and BT values 
in patients with BMI > 25 kg/m2 versus BMI ≤ 25 kg/m2. 
ADP-PA — ADP induced platelet aggregation; AA-PA 
— arachidonic acid induced platelet aggregation; BT 
— bleeding time; BMI — body mass index
ed with BMI (Tab. 4). The hsCRP was the only factor 
correlated with BT (inverse, weak correlation) (Tab. 5). 
The hsCRP was found to be the only independent 
factor influencing APD-PA according to multivariate 
analysis (p = 0.034). It explains only 2.5% of the vari-
ability in the platelet response to clopidogrel. We found 
serum concentrations of hsCRP, HDL-cholesterol and 
abdominal obesity to be independent factors influencing 
AA-PA (p = 0.000004). The regression model explains 
15.6% of the variability in the platelet response to aspirin.
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drome do not benefit from aspirin use due to high as-
pirin resistance. The prevalence of aspirin resistance 
achieved 46.9% compared to 20% in the control group 
(p = 0.033). According to multivariate logistic regres-
sion analysis, hsCRP concentration also significantly 
affected aspirin resistance [14]. This observation is in 
line with our own results showing significantly higher 
AA-PA in patients with increased levels of hsCRP 
and in subjects with BMI > 25 kg/m2 and confirmed 
by corresponding positive correlations and by mul-
tivariate analysis. Correlation of aspirin resistance 
with prothrombotic (fibrinogen) and proinflammatory 
(hsCRP) factors was also found in another study [15]. 
However, hsCRP levels correlated with aspirin resis-
tance only in patients with metabolic syndrome [15]. 
Kahraman et al. [16] observed aspirin resistance in 
21.9% of patients with metabolic syndrome. The fre-
quency of aspirin resistance in patients with metabolic 
syndrome was more common in patients with higher 
hs-CRP levels [16].
Possible explanations for this phenomenon, be-
sides underdosing of the drug and/or its reduced 
bioavailability subsequent to excess of adipose 
tissue, include enhanced platelet turnover, leading 
to unacetylated COX-1 and COX-2 in newly formed 
platelets as a source of aspirin-escaping thrombox-
ane formation; extraplatelet sources of thromboxane, 
driven by inflammatory triggers; and enhanced lipid 
peroxidation, activating platelets with a mechanism 
bypassing COX-1 acetylation or limiting COX-isozyme 
acetylation by aspirin [17]. 
On the other hand, Mao et al. [18] demonstrated that 
regulators of G protein signalling transcripts (according 
to mRNA levels) are elevated in aspirin-resistant plate-
lets from patients with metabolic syndrome. Regulators 
of G protein signalling, which accelerate the deactiva-
tion of G protein signalling, are expressed in platelets. 
G protein-coupled receptor signalling plays a crucial 
role in platelet activation [18]. The P2Y12 receptor 
inhibited by clopidogrel also belongs to the group of 
G protein-coupled receptors. Nevertheless, according 
to Erlinge et al. [19], the mechanism of incomplete 
platelet inhibition in clopidogrel poor-responders and in 
diabetic patients is lower plasma levels of its active me-
tabolite and not differences in platelet P2Y(12) receptor 
function. Interestingly, Pankert et al. [20] observed the 
impaired response to clopidogrel only in obese patients 
with metabolic syndrome, while obese patients without 
metabolic syndrome had no significant difference in 
platelet reactivity compared to non-obese patients [20].
In our study, the ADP-PA was significantly higher 
in patients with metabolic syndrome and in individuals 
with diabetes. Moreover, the hsCRP was found to be the 
only independent factor associated with high platelet 
reactivity in patients on clopidogrel.
Table 3. Correlations between ADP-PA and continuous 
variables 
Variable
R 
Spearman’s rank correlation 
coefficient p
TG 0.0559 0.449
HDL-C –0.0294 0.690
hsCRP 0.1886 0.011
BMI 0.1542 0.036
ADP-PA — ADP induced platelet aggregation; TG — triglycerides; 
HDL-C — high-density lipoprotein-cholesterol; hsCRP — high-sensitivity 
C-reactive protein; BMI — body mass index
Table 4. Correlations between AA-PA and continuous 
variables 
Variable
R 
Spearman’s rank 
correlation coefficient p
TG –0.0170 0.818
HDL-C 0.0070 0.924
hsCRP 0.3329 0.000004
BMI 0.1699 0.020
AA-PA — arachidonic acid induced platelet aggregation; TG — trigly-
cerides; HDL-C — high-density lipoprotein-cholesterol; hsCRP — high-
-sensitivity C-reactive protein; BMI — body mass index 
Table 5. Correlations between BT and continuous 
variables 
Variable
R 
Spearman’s rank correlation 
coefficient P
TG –0.0804 0.275
HDL-C –0.0084 0.908
hsCRP –0.1511 0.042
BMI –0.0973 0.186
BT — bleeding time; TG — triglycerides; HDL-C — high-density lipo-
protein-cholesterol; hsCRP — high-sensitivity C-reactive protein; BMI 
— body mass index
Discussion 
Platelets in patients affected by metabolic syndrome 
and diabetes mellitus show an enhanced activation 
state, mirrored by an increased expression of mem-
brane activation markers. These abnormalities are 
responsible for a pro-thrombotic condition, contributing 
to a high cardiovascular risk [13]. 
Moreover, features clustering in metabolic syndrome 
are responsible for the lower-than-expected response 
to antiplatelet agents. Cağirci et al. [14] postulated that 
a significant proportion of patients with metabolic syn-
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Platelets mediate and amplify the inflammatory 
response to ACS through adhesive interactions with 
leukocytes [21]. On the other hand, depressed respon-
siveness to aspirin and clopidogrel, due to antiplatelet 
resistance caused by systemic inflammation, may be 
observed in inflammatory diseases [22]. According to 
Malek et al., impaired antiplatelet response to clopi-
dogrel, but not to aspirin, may contribute to weaker 
anti-inflammatory response as assessed by hs-CRP 
in patients with ST-elevation MI [10]. In a study pub-
lished by Osmancik et al. [23], multivariate logistic 
regression revealed a higher body weight, apart from 
other factors, to be associated with an increased risk 
for being a non-responder to clopidogrel. More pro-
nounced inflammation, as expressed by plasma con-
centration of CRP, was also observed by Ge et al. [24] 
in patients with clopidogrel resistance compared to 
those with normal responsiveness. Furthermore, they 
revealed that diabetes mellitus was an independent 
predictor for unresponsiveness to clopidogrel after 
stent implantation according to multivariate analyses. In 
another study, elevated levels of CRP, WBC count and 
fibrinogen were associated with high platelet reactivity 
in patients on chronic clopidogrel treatment [25]. The 
correlation between ADP-PA and WBC count suggests 
platelets-leukocytes functional interaction, while the 
expression of the P2Y12 receptors on leukocytes sug-
gests that clopidogrel may act directly on these cells 
and not only on platelets. Clopidogrel treatment may 
reduce the influence of leukocytes on platelets and 
result in decreased leukocyte activation [26]. Grdinic 
et al. [27] revealed significantly elevated levels of in-
flammatory markers in non-responders to clopidogrel. 
Dual non-responders to clopidogrel and aspirin had 
a higher platelet count, LDL-cholesterol, and CRP, and 
lower HDL-cholesterol. 
Obesity, the pivotal factor in metabolic syndrome, is 
strongly associated with glucose metabolism disorders 
and inflammation. Thus, the results of our research, 
indicating relationships between these factors and the 
extent of platelet inhibition with aspirin and clopido-
grel in patients with ACS, are not surprising. Further 
studies are required to elucidate mechanisms of our 
observations and to define strategies to overcome 
shortcomings of investigated treatment in patients with 
metabolic syndrome.
Conclusion 
Metabolic syndrome, diabetes mellitus, obesity and 
increased hsCRP are determinants of low responsive-
ness to aspirin and clopidogrel in patients with ACS 
treated with PCI.
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